Letters to the Editor
Early Access
https://doi.org/10.4081/dr.2025.10527

Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA® analysis system

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 19 December 2025
397
Views
239
Downloads
Vitiligo, ruxolitinib, JAK inhibition, VISIA® skin analysis

Authors

Alberto Di Caro
alberto.dicaro@uniroma1.it
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Maria Elisabetta Greco
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Francesca Paola Sasso
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Francesca Feresin
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Ilaria Proietti
Dermatology Unit “Daniele Innocenzi”, ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Giovanni Pellacani
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Steven Paul Nisticò
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Annunziata Dattola
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.

Dear Editor,

Vitiligo is an acquired, chronic depigmenting disorder characterized by the progressive loss of epidermal melanocytes. Leukotrichia, present in approximately 10% to 60% of cases, results from the loss of melanocytes within the hair follicles. Clinically, it manifests as well-demarcated, nonscaling depigmented macules that may coalesce and expand over time. [...]

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet 2015;386:74-84. DOI: https://doi.org/10.1016/S0140-6736(14)60763-7
2. Ongenae K, Beelaert L, van Geel N, Naeyaert J. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol 2006;20:1-8 DOI: https://doi.org/10.1111/j.1468-3083.2005.01369.x
3. Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol 2020;38:621-48. DOI: https://doi.org/10.1146/annurev-immunol-100919-023531
4. Taïeb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007;20:27-35. DOI: https://doi.org/10.1111/j.1600-0749.2006.00355.x

How to Cite



1.
Di Caro A, Greco ME, Sasso FP, Feresin F, Proietti I, Pellacani G, et al. Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA® analysis system. Dermatol Reports [Internet]. 2025 Dec. 19 [cited 2026 Jun. 3];. Available from: https://journals.pagepress.net/dr/article/view/10527
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.